Page last updated: 2024-09-05

lanthanum carbonate and Bone Diseases, Metabolic

lanthanum carbonate has been researched along with Bone Diseases, Metabolic in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agapova, O; Fang, Y; Freedman, BI; Ginsberg, C; Hruska, KA; Malluche, H; Monier-Faugere, MC; Register, TC; Seifert, M; Sugatani, T1
Hanafusa, N1
Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W1
Yokoyama, K1
Akizawa, T; Mizobuchi, M; Nakazawa, A1
Hamano, T1
Bruschetta, E; Cozzolino, M; Cusi, D; Galassi, A; Giovenzana, ME; Montanari, E1
Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V1
Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H1

Reviews

8 review(s) available for lanthanum carbonate and Bone Diseases, Metabolic

ArticleYear
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Clinical calcium, 2015, Volume: 25, Issue:5

    Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification

2015
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
    Clinical calcium, 2010, Volume: 20, Issue:5

    Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer

2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
    Clinical calcium, 2010, Volume: 20, Issue:7

    Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic

2010
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
    Clinical calcium, 2011, Volume: 21, Issue:12

    Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D

2011
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
    Clinical calcium, 2012, Volume: 22, Issue:7

    Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D

2012
Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:16

    Topics: Animals; Bone Diseases, Metabolic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic

2012
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:8

    Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer

2006
CKD-MBD: impact on management of kidney disease.
    Clinical and experimental nephrology, 2007, Volume: 11, Issue:4

    Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins

2007

Trials

1 trial(s) available for lanthanum carbonate and Bone Diseases, Metabolic

ArticleYear
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Journal of the American Society of Nephrology : JASN, 2014, Volume: 25, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Disease Models, Animal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Klotho Proteins; Lanthanum; Male; Mice, Inbred C57BL; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Wnt1 Protein

2014